Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.55 |
| ▸ | COXFA4 | O00483 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.41 |
| ▸ | EDNRB | P24530 | 2/20 | 0.39 |
| ▸ | EDNRA | P25101 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12315470 | 1.00 | HSP90AA1 (0.55) | HSP90AA1COXFA4LMNAHTTMAPT | |
| SCHEMBL3455801 | 0.89 | HSP90AA1 (0.57) | HSP90AA1COXFA4LMNAHTTMAPT | |
| SCHEMBL13071769 | 0.89 | HSP90AA1 (0.43) | HSP90AA1COXFA4LMNAHTTMAPT | |
| SCHEMBL12315611 | 0.89 | HSP90AA1 (0.43) | HSP90AA1COXFA4LMNAHTTMAPT | |
| SCHEMBL12315569 | 0.87 | COXFA4 (0.59) | HSP90AA1COXFA4LMNAHTTMAPT | |
| SCHEMBL14666021 | 0.86 | HSP90AA1 (0.41) | HSP90AA1COXFA4LMNAHTTMAPT | |
| SCHEMBL14666190 | 0.86 | HSP90AA1 (0.41) | HSP90AA1COXFA4LMNAHTTMAPT | |
| SCHEMBL3469418 | 0.81 | HSP90AA1 (0.49) | HSP90AA1COXFA4LMNAHTTMAPT | |
| SCHEMBL3456476 | 0.80 | COXFA4 (0.77) | HSP90AA1COXFA4LMNAHTTMAPT | |
| SCHEMBL3456531 | 0.79 | HSP90AA1 (0.47) | HSP90AA1COXFA4LMNAHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8263042-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263042-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263042-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20090104118-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | CITIZENS BANK, N.A. | 2009-04-23 | — | — | US | disclosed |
| US-20090104118-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | CITIZENS BANK, N.A. | 2009-04-23 | — | — | US | disclosed |
| US-20090104118-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | CITIZENS BANK, N.A. | 2009-04-23 | — | — | US | disclosed |
| US-7485283-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485283-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485283-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING (US) | 2009-02-03 | — | — | US | disclosed |
| US-20050244332-A1 | Contrast agents for myocardial perfusion imaging | CITIZENS BANK, N.A. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090104118-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | HSP90AA1 1970/4885COXFA4 2119/4885LMNA 3348/4885 |
| US-20050244332-A1 | Contrast agents for myocardial perfusion imaging | TNNI3, TNNT2, FABP3 | HSP90AA1 1970/4885COXFA4 2119/4885LMNA 3348/4885 |
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | HSP90AA1 1970/4885COXFA4 2119/4885LMNA 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.